Health Care [ 4/12 ] | Biotechnology [ 11/75 ]
NASDAQ | Common Stock
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments.
The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema.
The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis.
Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 26 | -0.83 Increased by +34.65% | -0.96 Increased by +13.54% |
| Nov 6, 25 | -0.92 Increased by +31.34% | -1.01 Increased by +8.91% |
| Aug 7, 25 | -0.98 Increased by +35.53% | -1.03 Increased by +4.85% |
| May 7, 25 | -1.10 Increased by +1.79% | -1.27 Increased by +13.46% |
| Feb 20, 25 | -1.27 Increased by +13.01% | -1.32 Increased by +3.52% |
| Nov 7, 24 | -1.34 Increased by +2.90% | -1.38 Increased by +2.90% |
| Aug 8, 24 | -1.52 Decreased by -8.57% | -1.23 Decreased by -23.58% |
| May 9, 24 | -1.12 Increased by +4.27% | -1.38 Increased by +18.84% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 23.02 M Increased by +78.79% | -95.79 M Increased by +25.69% | Decreased by -416.15% Increased by +58.44% |
| Sep 30, 25 | 13.78 M Increased by +51.27% | -101.32 M Increased by +25.34% | Decreased by -735.19% Increased by +50.64% |
| Jun 30, 25 | 14.24 M Increased by +104.76% | -101.25 M Increased by +31.11% | Decreased by -710.81% Increased by +66.35% |
| Mar 31, 25 | 16.63 M Decreased by -42.54% | -114.33 M Decreased by -6.42% | Decreased by -687.61% Decreased by -85.19% |
| Dec 31, 24 | 12.87 M Increased by +771.57% | -128.90 M Increased by +2.47% | Decreased by -1.00 K% Decreased by -114.52% |
| Sep 30, 24 | 9.11 M Decreased by -24.02% | -135.71 M Decreased by -11.04% | Decreased by -1.49 K% Decreased by -46.15% |
| Jun 30, 24 | 6.96 M Decreased by -48.82% | -146.97 M Decreased by -18.83% | Decreased by -2.11 K% Decreased by -132.20% |
| Mar 31, 24 | 28.93 M Increased by +129.53% | -107.44 M Decreased by -4.18% | Decreased by -371.30% Increased by +54.61% |